An updated comprehensive meta-analysis of bivalirudin vs heparin use in primary percutaneous coronary intervention

American Heart Journal

Volumn 171, Issue 1, 2016, Pages 14-24

  Shah, Rahman ^a,b,f   Rogers, Kelly C ^c,f   Matin, Khalid ^d,f   Askari, Raza ^a,f   Rao, Sunil V ^e,f  

^a UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^d VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^e DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^f NC

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; PRASUGREL; TICAGRELOR; TIROFIBAN; ANTICOAGULANT AGENT; ANTITHROMBIN; HIRUDIN DERIVATIVE; PEPTIDE FRAGMENT; RECOMBINANT PROTEIN;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CARDIOVASCULAR MORTALITY; CORONARY STENT; DATA BASE; DRUG EFFICACY; DRUG SAFETY; HEART DISEASE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; STENT THROMBOSIS; SYSTEMATIC REVIEW; VASCULAR ACCESS; HEALTH; INCIDENCE; MORTALITY; MYOCARDIAL INFARCTION; POSTOPERATIVE COMPLICATIONS; SURVIVAL RATE; TRENDS;

ANTICOAGULANTS; ANTITHROMBINS; GLOBAL HEALTH; HEPARIN; HIRUDINS; HUMANS; INCIDENCE; MYOCARDIAL INFARCTION; PEPTIDE FRAGMENTS; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE COMPLICATIONS; RECOMBINANT PROTEINS; SURVIVAL RATE;

EID: 84951753046     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2015.10.006     Document Type: Article

References (42)

1. P.T. O'Gara, F.G. Kushner, D.D. Ascheim, and et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 61 2013 e78 e140
2. S.V. Rao, and E.M. Ohman Anticoagulant therapy for percutaneous coronary intervention Circ Cardiovasc Intervent 3 2010 80 88
3. S. Windecker, P. Kolh, F. Alfonso, and et al. 2014 ESC/EACTS guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) Eur Heart J 35 2014 2541 2619
4. G.W. Stone, B. Witzenbichler, G. Guagliumi, and et al. Bivalirudin during primary PCI in acute myocardial infarction N Engl J Med 358 2008 2218 2230
5. P.G. Steg, A. van 't Hof, C.W. Hamm, and et al. Bivalirudin started during emergency transport for primary PCI N Engl J Med 369 2013 2207 2217
6. U. Zeymer, A. van 't Hof, J. Adgey, and et al. Bivalirudin is superior to heparins alone with bailout GP IIb/IIIa inhibitors in patients with ST-segment elevation myocardial infarction transported emergently for primary percutaneous coronary intervention: a pre-specified analysis from the EUROMAX trial Eur Heart J 35 2014 2460 2467
7. Y. Han, J. Guo, Y. Zheng, and et al. Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial JAMA 313 2015 1336 1346
8. S. Subherwal, E.D. Peterson, D. Dai, and et al. Temporal trends in and factors associated with bleeding complications among patients undergoing percutaneous coronary intervention: a report from the National Cardiovascular Data CathPCI Registry J Am Coll Cardiol 59 2012 1861 1869
9. A. Shahzad, I. Kemp, C. Mars, and et al. Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial Lancet 384 2014 1849 1858
10. S. Hempel, J.N. Miles, M.J. Booth, and et al. Risk of bias: a simulation study of power to detect study-level moderator effects in meta-analysis Syst Rev 2 2013 107
11. D. Moher, L. Shamseer, M. Clarke, and et al. Preferred Reporting Items for Systematic reviews and Meta-Analysis protocols (PRISMA-P) 2015 statement Syst Rev 4 2015 1
12. M. Valgimigli, E. Frigoli, S. Leonardi, and et al. Bivalirudin or unfractionated heparin in acute coronary syndromes N Engl J Med 373 11 2015 997 1009
13. J.P. Higgins, S.G. Thompson, J.J. Deeks, and et al. Measuring inconsistency in meta-analyses BMJ 327 2003 557 560
14. A. Sutton, K. Abrams, D. Jones, and et al. Methods for meta-analysis in medical research 2000 Wiley Chichester, UK
15. J.A. Sterne, A.J. Sutton, J.P. Ioannidis, and et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials BMJ 343 2011 d4002
16. S. Schulz, G. Richardt, K.L. Laugwitz, and et al. Prasugrel plus bivalirudin vs. clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction Eur Heart J 35 2014 2285 2294
17. S. Bangalore, B. Toklu, A. Kotwal, and et al. Anticoagulant therapy during primary percutaneous coronary intervention for acute myocardial infarction: a meta-analysis of randomized trials in the era of stents and P2Y12 inhibitors BMJ 349 2014 g6419
18. O.F. Bertrand, S.S. Jolly, S.V. Rao, and et al. Meta-analysis comparing bivalirudin versus heparin monotherapy on ischemic and bleeding outcomes after percutaneous coronary intervention Am J Cardiol 110 2012 599 606
19. M.A. Cavender, and M.S. Sabatine Bivalirudin versus heparin in patients planned for percutaneous coronary intervention: a meta-analysis of randomised controlled trials Lancet 384 2014 599 606
20. M.S. Lee, H. Liao, T. Yang, and et al. Comparison of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in patients undergoing an invasive strategy: a meta-analysis of randomized clinical trials Int J Cardiol 152 2011 369 374
21. E.P. Navarese, V. Schulze, F. Andreotti, and et al. Comprehensive meta-analysis of safety and efficacy of bivalirudin versus heparin with or without routine glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndrome J Am Coll Cardiol Intv 8 2015 201 213
22. A.A. Bavry, I.Y. Elgendy, A. Mahmoud, and et al. Critical appraisal of bivalirudin versus heparin for percutaneous coronary intervention: a meta-analysis of randomized trials PLoS One 10 2015 e0127832
23. D. Capodanno, G. Gargiulo, P. Capranzano, and et al. Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary PCI: An updated meta-analysis of 10,350 patients from five randomized clinical trials Eur Heart J Acute Cardiovasc Care 2015
24. S. Cassese, R.A. Byrne, K.L. Laugwitz, and et al. Bivalirudin versus heparin in patients treated with percutaneous coronary intervention: a meta-analysis of randomised trials EuroIntervention 11 2015 196 203
25. G. De Luca, E. Cassetti, M. Verdoia, and et al. Bivalirudin as compared to unfractionated heparin among patients undergoing coronary angioplasty: a meta-analysis of randomised trials Thromb Haemost 102 2009 428 436
26. G. Ferrante, M. Valgimigli, P. Pagnotta, and et al. Bivalirudin versus heparin in patients with acute myocardial infarction: a meta-analysis of randomized trials Catheter Cardiovasc Interv 86 2015 378 389
27. T. Kinnaird, G. Medic, G. Casella, and et al. Relative efficacy of bivalirudin versus heparin monotherapy in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: a network meta-analysis J Blood Med 4 2013 129 140
28. M.J. Lipinski, T. Lhermusier, R.O. Escarcega, and et al. Bivalirudin versus heparin for percutaneous coronary intervention: an updated meta-analysis of randomized controlled trials Cardiovasc Revasc Med 15 2014 315 322
29. E.P. Navarese, F. Andreotti, M. Kolodziejczak, and et al. Comparative efficacy and safety of anticoagulant strategies for acute coronary syndromes. Comprehensive network meta-analysis of 42 randomised trials involving 117,353 patients Thromb Haemost 2015 114
30. M. Verdoia, A. Schaffer, L. Barbieri, and et al. Bivalirudin as compared to unfractionated heparin in patients undergoing percutaneous coronary revascularization: a meta-analysis of 22 randomized trials Thromb Res 135 2015 902 915
31. R. Nairooz, P. Sardar, H. Amin, and et al. Meta-analysis of randomized clinical trials comparing bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention and in patients with ST-segment elevation myocardial infarction Am J Cardiol 114 2014 250 259
32. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB Trial. Thrombolysis in Myocardial Ischemia Circulation 89 1994 1545 1556
33. D. Rott, and D. Leibowitz STEMI and NSTEMI are two distinct pathophysiological entities Eur Heart J 28 2007 2685 [author reply 2685]
34. A. Cipriani, J.P. Higgins, J.R. Geddes, and et al. Conceptual and technical challenges in network meta-analysis Ann Intern Med 159 2013 130 137
35. E.D. Peterson, D. Dai, E.R. DeLong, and et al. Contemporary mortality risk prediction for percutaneous coronary intervention: results from 588,398 procedures in the National Cardiovascular Data Registry J Am Coll Cardiol 55 2010 1923 1932
36. S.J. Pocock, R. Mehran, T.C. Clayton, and et al. Prognostic modeling of individual patient risk and mortality impact of ischemic and hemorrhagic complications: assessment from the Acute Catheterization and Urgent Intervention Triage Strategy trial Circulation 121 2010 43 51
37. G.W. Stone, T. Clayton, E.N. Deliargyris, and et al. Reduction in cardiac mortality with bivalirudin in patients with and without major bleeding: The HORIZONS-AMI trial (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) J Am Coll Cardiol 63 2014 15 20
38. G.D. Dangas, A. Caixeta, R. Mehran, and et al. Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarction Circulation 123 2011 1745 1756
39. R. Shah Bivalirudin versus heparin use for patients undergoing PPCI Lancet 385 9982 2015 2045
40. R. Mehran, S.V. Rao, D.L. Bhatt, and et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium Circulation 123 2011 2736 2747
41. G.W. Stone, B. Witzenbichler, G. Guagliumi, and et al. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial Lancet 377 2011 2193 2204
42. P. Clemmensen, S. Wiberg, A. Van't Hof, and et al. Acute stent thrombosis after primary percutaneous coronary intervention: insights from the EUROMAX trial (European Ambulance Acute Coronary Syndrome Angiography) J Am Coll Cardiol Intv 8 2015 214 220